NH
Nephrocare Health
Mainboard₹871 Cr issue
+6.52%
Listing gain over issue price
Issue size
₹871 Cr
1 lot at cut-off
₹14,720
Lot size
32shares
Allotment
15 Dec 2025
Listing
17 Dec 2025
Listing performance
Issue price
₹460
Listed at
₹490
Listing-day close
₹471.60
Latest price
₹674.95
Listing gain
+6.52%
Return since listing
+46.73%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
₹40
3 observations recorded — too few to plot a trend.
Day-wise premium · 3 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 17 Dec 2025 | ₹40 | +8.70% | ₹1,000 | ₹500 | ₹1,280 |
| 16 Dec 2025 | ₹37 | +8.04% | ₹900 | ₹497 | ₹1,184 |
| 15 Dec 2025 | ₹37 | +8.04% | ₹900 | ₹497 | ₹1,184 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- Listing date
- 17 Dec 2025
- Face value
- ₹2 per share
- Issue price
- ₹460 per share
- Lot size
- 32 shares
- Total issue size
- ₹871 Cr
- Market cap at offer price
- ₹4,615 Cr
- Promoter holding
- 78.90% → 71.49% pre-issue → post-issue
- ISIN
- INE428V01029
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- ICICI Securities Ltd.
- Registered office
- 5 th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No.64, Madhapur, Shaikpet, Telangana
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 56,57,919 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 32 shares per lot, in multiples, at ₹460
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 32 | ₹14,720 |
| Retail (max) | 13 | 416 | ₹1,91,360 |
| S-HNI (min) | 14 | 448 | ₹2,06,080 |
| S-HNI (max) | 67 | 2,144 | ₹9,86,240 |
| B-HNI (min) | 68 | 2,176 | ₹10,00,960 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
56,57,919
Anchor portion
₹260 Cr
at ₹460 per share
Valuation and performance
Valuation at offer price
₹460 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 7.24 | 2.84 |
| P/E (×) | 63.54 | 161.97 |
| Price to book (×) | 7.72 | — |
| Market cap | — | ₹4,615 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 13.19%
- ROCE
- 18.67%
- PAT margin
- 8.88%
- EBITDA margin
- 22.05%
- NAV per share
- ₹59.56
- Price to book
- 7.72
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Nephrocare Health
NephroPlus (Nephrocare Health Services Limited) is India's largest dialysis service provider by number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA. As of September 30, 2025, the company operates 519 dialysis clinics across 288 cities in India and 51 clinics internationally in Nepal (6), Philippines (41), and Uzbekistan (4). The company generates revenue through three primary clinic models: captive clinics operated within private hospitals under revenue-sharing arrangements, standalone clinics independently owned and operated, and public-private partnership (PPP) clinics under government contracts. Revenue from operations was ₹7,558.12 million in Fiscal 2025, with the company serving 33,076 patients and performing 3.30 million treatments.
Company Analysis
from RHPNephroPlus operates India's largest dialysis service provider network, offering hemodialysis and related nephrology services across India and internationally through captive, standalone, and public-private partnership clinics.
NephroPlus (Nephrocare Health Services Limited) is India's largest dialysis service provider by number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA. As of September 30, 2025, the company operates 519 dialysis clinics across 288 cities in India and 51 clinics internationally in Nepal (6), Philippines (41), and Uzbekistan (4). The company generates revenue through three primary clinic models: captive clinics operated within private hospitals under revenue-sharing arrangements, standalone clinics independently owned and operated, and public-private partnership (PPP) clinics under government contracts. Revenue from operations was ₹7,558.12 million in Fiscal 2025, with the company serving 33,076 patients and performing 3.30 million treatments.
Objects of the Issue
- Funding capex for opening new dialysis clinics in India ₹1,291.06 million p.66
- Funding capital expenditure by our Company for opening new dialysis clinics in India p.103
- Prepayment/repayment, in full or part, of certain outstanding borrowings availed by our Company p.103
- General corporate purposes p.103
- Capital expenditure by our Company for opening new dialysis clinics in India ₹1,291.06 million p.192
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by our Company ₹1,359.99 million p.192
- General corporate purposes [●] p.192
- Not specified in this document section
- Funding capex for expansion of kidney care centers ₹3,534.05 million p.581
Issue Structure
- Face Value
- ₹10
Business Model
NephroPlus generates revenue through dialysis treatments performed at its network of clinics. Revenue sources include: (1) captive clinics within private hospitals (36.51% of revenue in H1 FY2026), typically on revenue-sharing basis; (2) PPP clinics operated under government contracts (30.96% of revenue in H1 FY2026), with pricing determined by government agencies; (3) standalone clinics independently operated; and (4) premium value-added services including home hemodialysis. The company also generates ancillary revenue from dialysis-related services. Revenue per treatment averaged ₹2,531.05 in H1 FY2026.
Business Segments
Dialysis clinics operated within private hospital premises under contractual revenue-sharing arrangements. As of September 30, 2025, the company operated 272 captive clinics.
Dialysis clinics operated under public-private partnership contracts awarded by government agencies through competitive bidding. As of September 30, 2025, the company operated 180 PPP clinics across multiple states.
Independently owned and operated dialysis clinics. As of September 30, 2025, the company operated 67 standalone clinics.
Dialysis clinics and services provided outside India in Nepal, Philippines, and Uzbekistan.
Traditional dialysis services provided at clinic locations, with most clinics in India operating as captive clinics within partner hospital premises on revenue sharing arrangements or on PPP basis
Dialysis services provided at patients' homes where clinician/dialysis technician visits customer's home to support with the dialysis process including cannulation
Program where patients can continue treatment while traveling, with the company managing travel, accommodation, and treatment logistics
Provision of haemodialysis treatments through captive clinics (operated within private hospitals on revenue-sharing basis), standalone clinics (independent operations), and PPP clinics (operated in government facilities with state government partnerships). Services include standard haemodialysis, hemodiafiltration, and other critical care services such as plasmapheresis, continuous renal replacement therapy.
Home haemodialysis (HHD) where equipment is permanently set up at patient's home; Dialysis on Call (DoC) where mobile dialysis setup is brought to patient's home or hospital; Dialysis on Wheels (DoW) providing fully operational dialysis setup in an ambulance van outside patient's home or office.
Sale of pharmacy and consumables, liabilities no longer required written back, scrap sales, sponsorship income, training and admission fees.
Company-owned and operated dialysis clinics providing hemodialysis and peritoneal dialysis services directly to patients
Dialysis clinics operated under government contracts in India and Uzbekistan where the company receives government-funded patient fees; as of September 30, 2025, company had entered into 52.41% partnerships with hospitals and hospital chains across India
Nephrocare establishes and operates dialysis units within partner hospital premises on a revenue-sharing basis; end-to-end clinic setup including investment in dialysis machines and RO water systems, staffing, consumables procurement, and implementation of RenAssure protocol
Dietician consultations, mobile dialysis vans (DoW), home hemodialysis (HHD), dialysis on call (DoC), clinical research services, dialyzer reprocessing through Renova system, and patient engagement through digital platforms
Provision of dialysis treatments to patients through a chain of kidney care clinics
Dialysis clinics operated in partnership with hospitals or owned facilities
Dialysis clinics operated under public-private partnership arrangements
Independently operated dialysis clinics
Provision of dialysis treatments including haemodialysis, hemodiafiltration, continuous renal replacement therapy, plasmapheresis, and sale of dialysis-related pharmacy products across India, Philippines, Uzbekistan and Nepal
SWOT Analysis
Strengths
- • Market leadership in dialysis services in India with significant scale advantages(p.23)
- • Extensive geographic reach with pan-India network across multiple cities and states(p.23)
- • Global position as largest dialysis provider in Asia and fifth largest globally(p.23)
- • Strong financial performance with consistent revenue and EBITDA growth(p.23)
- • Diversified revenue model with significant presence across captive, PPP, and standalone clinics(p.28)
- • Market-leading scale and geographic reach in India(p.71)
- • Proven international expansion capability(p.71)
- • Successful track record of acquisitions and integration(p.73)
- • Quality accreditations and certifications(p.68)
- • Diversified revenue streams across clinic models(p.55)
- • Established market position with significant scale in dialysis services(p.98)
- • Diversified service delivery model across multiple care settings(p.98)
- • Established presence in international markets(p.99)
- • India's and Asia's largest dialysis provider with dominant market position(p.310)
- • Asset-light, capital-efficient business model enabling rapid clinic expansion(p.305)
- • Geographic diversification across India with 77.35% clinics in tier II and tier III cities(p.303)
- • Only Indian dialysis provider scaled internationally across multiple countries(p.303)
- • Protocol-driven clinical excellence with proprietary RenAssure quality system(p.306)
- • Proven acquisition integration track record with DaVita India and Philippines network roll-ups(p.315)
- • Vertical integration for key consumables reducing costs and supply chain dependency(p.314)
- • Patient-centric leadership with co-founder on dialysis for 28 years(p.308)
- • Hospital partnership model enabling efficient expansion without capital burden(p.330)
- • Standardized RenAssure clinical protocol ensuring quality and safety across network(p.331)
- • Significant scale with 52.41% of clinics operating as hospital partnerships(p.330)
- • Proprietary Renova dialyzer reprocessing system with cloud-enabled technology(p.333)
- • Enpidia training academy producing standardized, protocol-compliant clinical staff(p.343)
- • Strong accreditation credentials with 145 NABH-accredited clinics and 3 JCI-accredited clinics(p.340)
- • Multiple digital platforms enhancing patient engagement and clinical outcomes(p.334)
- • Published research in leading peer-reviewed nephrology journals(p.333)
- • Experienced founder with medical and business expertise(p.388)
- • Strong board composition with healthcare and investment expertise(p.388)
- • Reputable institutional investor backing(p.409)
- • Diversified portfolio of institutional and PE investors(p.406)
- • Only Indian dialysis provider scaled internationally with global network(p.509)
- • Most widely distributed dialysis network in India across tier II and tier III cities(p.509)
- • Asset-light operating model enabling rapid deployment and breakeven(p.510)
- • Strong revenue growth trajectory and margin expansion(p.528)
- • Improving cost of materials efficiency through scale(p.531)
Weaknesses
- • High dependence on captive clinic contracts which could be terminated or not renewed(p.28)
- • Reliance on PPP contracts subject to competitive bidding and government decisions(p.28)
- • Dependence on healthcare professionals for business continuity(p.28)
- • Exposure to operational and medical risks including quality and compliance challenges(p.28)
- • Business interruption risks at dialysis clinics could cause significant losses(p.28)
- • High dependence on captive clinic contracts subject to non-renewal risk(p.55)
- • Significant exposure to PPP contract concentration and tender risks(p.56)
- • High attrition rate among healthcare professionals(p.60)
- • High geographic concentration of revenue in southern India(p.90)
- • Substantial losses in certain subsidiaries affecting overall profitability(p.75)
- • High operational dependence on manual workforce with unionization risk(p.98)
- • Significant medico-legal liability exposure in off-clinic home hemodialysis services(p.98)
- • High employee attrition affecting operational stability(p.101)
- • Dependency on leased premises with renewal and termination risks(p.100)
- • Controlling shareholder concentration limiting minority shareholder influence(p.100)
- • Limited experience of corporate promoters in dialysis business(p.101)
- • Key person dependence on individual promoter and senior management(p.101)
- • H1 FY26 profitability decline with PAT margin compressed to 3.00% versus 8.88% prior year(p.318)
- • High net debt to EBITDA ratio at 1.12x as of September 30, 2025 indicating leverage concerns(p.310)
- • Significant international revenue exposure (39.96%) creating currency and execution risk(p.310)
- • Limited dialysis technician workforce with only 357 Enpidia-trained technicians(p.315)
- • Below-optimal treatment frequency of 2.26x per week versus WHO norms of 3-4x weekly(p.306)
- • Dependence on hospital partnerships creating operational integration risk(p.330)
- • Reliance on contract manufacturers for critical consumables(p.338)
- • Significant working capital requirements for operations(p.336)
- • Limited portfolio diversification with concentration in dialysis services(p.355)
- • Dependence on skilled clinical workforce with unionization risks not yet materialized(p.342)
- • Dependence on limited number of investors with exit obligations(p.392)
- • Complex capital structure with multiple share classes and instruments(p.431)
- • High finance costs relative to profitability(p.430)
- • Majority of directors appointed as nominees of investors(p.389)
- • High healthcare professional fees as percentage of revenue(p.532)
- • Dependence on hospital fees with revenue concentration(p.490)
- • High capital intensity of acquisitions creating goodwill(p.496)
- • Integration challenges from rapid acquisition strategy(p.510)
- • Statutory audit observations and audit trail recording deficiencies(p.539)
- • Related party transactions with potential conflicts of interest(p.539)
- • Dependence on bank financing with restrictive covenants(p.544)
- • Material pending litigation over revenue sharing obligations(p.547)
- • Outstanding tax claims against company and subsidiaries(p.550)
- • Material creditor dependency and MSME payment obligations(p.551)
Opportunities
- • Growing global dialysis services market with substantial projected growth(p.23)
- • Opportunity to expand clinics in India through capital investment from IPO proceeds(p.24)
- • Strong market position enabling further expansion and market consolidation(p.28)
- • Large and growing dialysis market in India(p.92)
- • Expansion into emerging international markets(p.96)
- • Growth in organized dialysis sector market share(p.92)
- • Off-clinic and home hemodialysis market development(p.97)
- • Increasing prevalence of chronic kidney disease and demand drivers(p.92)
- • Expansion of home-based dialysis services and novel treatment delivery models(p.98)
- • Growth in emerging markets with PPP model adoption(p.99)
- • Massive underpenetrated Indian market with only 1 in 15 ESRD patients accessing dialysis(p.307)
- • Fast-growing organized market with 14.4% CAGR versus 12.4% for unorganized peers(p.318)
- • High-growth Philippines market expanding at 22.6% CAGR with 3x higher reimbursement rates than India(p.319)
- • Government healthcare expansion via Ayushman Bharat covering 12 crore families(p.319)
- • Hospital outsourcing trend with 90% of Indian dialysis clinics in urban areas creating rural opportunity(p.304)
- • Expansion into new markets (Malaysia, Kazakhstan, CIS) with favorable PPP dynamics(p.320)
- • Expansion in organized dialysis market in APAC with less than 25% market penetration(p.341)
- • Growth through PPP clinics and government partnerships(p.362)
- • International expansion with entry into Philippines, Uzbekistan, Saudi Arabia and Nepal(p.357)
- • Off-clinic dialysis services offering flexibility for patients in underserved areas(p.335)
- • Research and clinical trial capabilities supporting innovation and evidence generation(p.333)
- • Enpidia franchise model enabling rapid workforce scaling across geographies(p.343)
- • Geographic expansion into multiple countries(p.435)
- • Multiple subsidiaries in Philippines and international markets(p.437)
- • Acquisition and consolidation strategy in healthcare services(p.433)
- • International expansion in Philippines and Uzbekistan markets(p.510)
- • Expansion potential in India across tier II and tier III cities(p.509)
- • Growing patient base and treatment volumes(p.509)
- • Standardised protocols enabling scalable replication(p.510)
- • Expansion through international subsidiaries(p.553)
- • Strong intellectual property portfolio for brand protection(p.554)
- • Capacity for network expansion through new clinic registrations(p.554)
Threats
- • Regulatory risks and compliance costs in healthcare industry(p.28)
- • Foreign currency and interest rate fluctuation risks(p.28)
- • Risk of contract termination and blacklisting in PPP arrangements(p.28)
- • No assurance of active trading or sustained price after listing(p.2)
- • Risk of non-renewal of captive clinic contracts due to competitive and commercial pressures(p.55)
- • PPP tender losses to competition(p.58)
- • Government reimbursement rate reductions and regulatory uncertainty(p.63)
- • Intense competition from established healthcare providers(p.91)
- • Foreign exchange volatility affecting international operations(p.65)
- • Supply chain disruption and input cost inflation for medical consumables(p.80)
- • Regulatory compliance costs and implementation uncertainty(p.63)
- • Technological disruption potentially reducing dialysis demand(p.95)
- • Novel market uncertainties in holiday dialysis program segment(p.98)
- • Potential supply chain disruptions affecting medical consumables delivery(p.99)
- • Regulatory uncertainty and changing labor laws increasing compliance costs(p.98)
- • Regulatory requirements for free or subsidized dialysis services(p.104)
- • Tax regime changes and compliance uncertainty in operating jurisdictions(p.109)
- • Foreign exchange and repatriation risks affecting international operations(p.109)
- • Heavy treatment cost burden on patients (₹1,000-₹3,500 per session) limiting affordability(p.301)
- • Severe shortage of trained nephrologists and dialysis technicians nationally(p.281)
- • Geographic disparities with dialysis services concentrated in urban areas limiting rural access(p.301)
- • Poor patient adherence with 50% of patients not completing prescribed 3x weekly dialysis frequency(p.280)
- • Late diagnosis with 50% of CKD patients reaching ESRD stage before seeking treatment(p.280)
- • Regulatory complexity with delayed empanelment under government health schemes(p.301)
- • Risk of high infection rates and patient complications affecting outcomes and retention(p.301)
- • Competition from international and domestic dialysis service providers(p.341)
- • Risk of losing accreditations affecting clinic revenues and brand reputation(p.340)
- • Dependence on favorable supplier terms and vulnerability to cost increases(p.338)
- • Import restrictions on raw materials affecting international operations(p.339)
- • Workforce supply disruptions through strikes, wage demands, or labor disputes(p.343)
- • Insurance coverage gaps potentially exposing company to uninsured losses(p.341)
- • Lease termination or renewal risks affecting clinic operations(p.344)
- • Healthcare regulatory complexity across multiple jurisdictions(p.435)
- • Foreign exchange exposure from international operations(p.430)
- • Exposure to healthcare sector cyclicality and regulatory changes(p.443)
- • Reliance on leased premises with renewal uncertainties(p.510)
- • Exposure to government reimbursement rate changes(p.531)
- • Unresolved competitor dispute over government hospital operating rights(p.489)
- • Volatility in dialysis consumable costs and supply chain risks(p.511)
- • Regulatory compliance and licensing delays(p.553)
- • Potential future audit findings and financial statement adverse effects(p.80)
- • Risk of credit rating downgrade impacting financing(p.544)
- • Outstanding litigation by subsidiary in Philippines(p.548)
- • Pending regulatory discharge permits for Philippines operations(p.553)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Aditya Ajwani | Shareholder (non-resident) | — | — |
| Nagraj and Sarita | Shareholder (non-resident) | — | — |
| William H Stadtlander III | Shareholder (non-resident) | — | — |
| IPEF II (Investcorp Private Equity Fund II) | Shareholder (acquired 192,286 equity shares) | — | — |
| SeaBean Dialysis Partners II (Mauritius Based) | Previous Shareholder | — | — |
| Vikram Vuppala | Promoter | 11.14% | — |
| BVP Trust | Promoter | 9.90% | — |
| Edoras Investment Holdings Pte. Ltd. | Promoter | 34.28% | — |
| HPL | Promoter | 8.08% | — |
| IPEF II | Promoter | 7.40% | — |
| IGOF | Promoter | 0.66% | — |
| Vikram Vuppala | Individual Promoter | 11.14% | [●] |
| BVP Trust | Promoter | 9.90% | [●] |
| Edoras Investment Holdings Pte. Ltd. | Promoter | 34.28% | [●] |
| HPL | Promoter | 8.08% | [●] |
| IPEF II | Promoter | 7.40% | [●] |
| IGOF | Promoter | 0.66% | [●] |
| Pankaja Gatuku | Promoter Group | 0.02% | [●] |
| Manvi Family Trust | Promoter Group | 1.87% | [●] |
| Viraaj Family Trust | Promoter Group | 1.96% | [●] |
| Quadria Capital India Fund III | Promoter Group | 1.99% | [●] |
| Vikram Vuppala | Promoter | — | — |
| Vaibhav Joshi | Promoter | — | — |
| Rohit Singh | Promoter | — | — |
| Rajan Nayyar | Promoter | — | — |
| Manvi Family Trust | Promoter | — | — |
| Viraaj Family Trust | Promoter | — | — |
| Sukaran Singh Saluja | Promoter | — | — |
| Sohil Bhagat | Promoter | — | — |
| Prasan Dilip Shah | Promoter | — | — |
| Ravi Dikshit | Promoter | — | — |
| Yadagiri Sai Kiran | Promoter | — | — |
| Satish Mootha | Promoter | — | — |
| Suresh Dirisala | Promoter | — | — |
| Ravinder Kumar Singh | Promoter | — | — |
| Kamal D Shah | Promoter | — | — |
| Pallvit Jain | Promoter | — | — |
| Vikram Vuppala | Promoter/Individual Promoter | — | — |
| Kamal D. Shah | Co-founder/Promoter | — | — |
| Vikram Vuppala | Founder and Chairman & Managing Director | — | — |
| Kamal D Shah | Co-founder | — | — |
| Vikram Vuppala | Founder and Promoter | — | — |
| Bessemer Venture Partners Trust (BVP Trust) | Corporate Promoter | 9.90% | — |
| Edoras Investment Holdings Pte. Ltd. | Corporate Promoter | 34.28% | — |
| Healthcare Parent Limited (HPL) | Corporate Promoter | 8.08% | — |
| Investcorp Private Equity Fund II (IPEF II) | Corporate Promoter | 7.40% | — |
| Investcorp Growth Opportunity Fund (IGOF) | Corporate Promoter | 0.66% | — |
| Vikram Vuppala | Promoter | 1.89% (equity shares as at 31 March 2025) | 10.73% (as at 30 September 2025 - post stock split and bonus issuance) |
| Edoras Investment Holdings Pte. Ltd | Promoter | 34.22% (equity shares as at 31 March 2025) | 41.43% (as at 30 September 2025) |
| InvestCorp Private Equity Fund II (IPF-II) | Promoter | 17.98% (equity shares as at 31 March 2025) | 8.59% (as at 30 September 2025) |
| Healthcare Parent Limited (HPL) | Promoter | 23.21% (equity shares as at 31 March 2025) | 11.09% (as at 30 September 2025) |
| Bessemer Venture Partners Trust (BVP) | Promoter | 1.01% (equity shares as at 31 March 2025) | 0.48% (as at 30 September 2025) |
| Vikram Vuppala | Promoter | — | — |
| Edoras Investment Holdings Pte. Ltd | Promoter Group | — | — |
| BVP | Promoter Group | — | — |
| IPF - II | Promoter Group | — | — |
| HPL | Promoter Group | — | — |
| Investcorp Growth Opportunity Fund | Promoter Group | — | — |
| IPEF II | Selling Shareholder | — | — |
| HPL | Selling Shareholder | — | — |
| IGOF | Selling Shareholder | — | — |
| Edoras Investment Holdings Pte. Ltd. | Selling Shareholder | — | — |
| IIPEOL | Selling Shareholder | — | — |
| IFC | Selling Shareholder | — | — |
| 360 One Series 9 | Selling Shareholder | — | — |
| 360 One Series 10 | Selling Shareholder | — | — |
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.